Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial
Posted inClinical Updates Wellness & Lifestyle

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increased coronary events in the aspirin-free group.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inClinical Updates Wellness & Lifestyle

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.